Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product. The post Mesoblast ...

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside. The post This rising ASX ...

As of Friday, January 09, Mesoblast Limited’s MESO share price has surged by 7.70%, which has investors questioning if this ...

The average one-year price target for Mesoblast Ltd - ADR (NASDAQ:MESO) has been revised to 4.64 / share. This is an increase of 13.98% from the prior estimate of 4.07 dated June 1, 2023. The price ...

This biotech is hitting new highs on Friday. Let's find out why. The post Why are Mesoblast shares jumping 10% to a 52-week high? appeared first on The Motley Fool Australia.

On Monday, Mesoblast Ltd. (NASDAQ:MESO) announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor ...

Mesoblast (ASX:MSB) has seen its shares dip on Monday morning out the gate as some investors struggle to digest what exactly ...

Mesoblast Ltd (NASDAQ: MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil. What Happened: ...

In trading on Monday, shares of Mesoblast Ltd (Symbol: MESO) crossed below their 200 day moving average of $11.43, changing hands as low as $11.32 per share. Mesoblast Ltd shares are currently trading ...

March 8 (Reuters) - Shares of Australia's Mesoblast Ltd (MSB.AX), opens new tab rallied more than 23% on Wednesday after the U.S. Food and Drug Administration (FDA) agreed to review the company's lead ...

Article ‘Count’ and ‘Share’ for Mesoblast, Ltd based on listed parameters only. According to the parameters selected above, there are no articles from Mesoblast, Ltd from 1 September 2024 - 31 August ...